Binding aspects of baicalein to HIV-1 integrase.
Human immunodeficiency virus type 1 (HIV-1) integrase is an essential enzyme in the life cycle of the virus. It is responsible for catalyzing the insertion of the viral genome into the host cell chromosome. This integrase is an attractive target for the design of a HIV antiviral drug, because integrase has no human counterpart. In order to know the interaction mode of HIV-1 integrase with its inhibitor, we investigated the effect of the inhibitor, baicalein, on the conformation of the HIV-1 integrase catalytic domain [IN-(50-212/F185K)] using fluorescence and circular dichroism (CD) spectroscopy. We found that baicalein binds to the hydrophobic region of the HIV-1 integrase catalytic core domain. This binding of baicalein induces the conformational change of the enzyme. We also found that the binding ratio of baicalein to the HIV-1 integrase catalytic domain is 2:1.
Ahn
H C
HC
Department of Pharmacy, Seoul National University, Korea.
Lee
S Y
SY
Kim
J W
JW
Son
W S
WS
Shin
C G
CG
Lee
B J
BJ
D002942:Circular Dichroism; D004791:Enzyme Inhibitors / Q000378:metabolism; D044950:Flavanones; D005419:Flavonoids / Q000378:metabolism*; D019427:HIV Integrase / Q000737:chemistry / Q000378:metabolism*; D015497:HIV-1 / Q000201:enzymology* / Q000378:metabolism; D006801:Humans; D015394:Molecular Structure; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D013050:Spectrometry, Fluorescence
D004791:Enzyme Inhibitors; D044950:Flavanones; D005419:Flavonoids; C006680:baicalein; D019427:HIV Integrase